Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Plby Group Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Plby Group Inc trades at $0.97 (market cap $122.20M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 72.6× Plby Group Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| KYMR | PLBY | |
|---|---|---|
Market Cap | $8.87B | $122.20M |
Volume | 779,107 | 540,321 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $2.71 |
52-Week Low | $55.80 | $0.98 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $8.26B | $267.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PLBY trades at $0.99, down 0.32% with a bearish technical signal. The company shows improving fundamentals with revenue stabilizing around $121M in 2025 and narrowing losses from -$278M in 2022 to -$13M. Recent Q2 2026 earnings beat expectations with positive operating cash flow. Analyst sentiment remains strong with 75% buy ratings, while technical indicators show oversold conditions with RSI at neutral levels.
The outlook suggests cautious optimism as PLBY demonstrates operational improvement and debt reduction, though negative shareholder equity and high P/E ratio of 51 present valuation concerns. Key risks include persistent negative equity and competitive pressures in the consumer discretionary space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
